Amgen announced a $600 million investment to expand its research and development site in Thousand Oaks, California. The state-of-the-art facility will focus on accelerating next-generation drug discovery supported by automation and digital technologies. This move is part of broader US manufacturing investments totaling billions in recent years and aligns with supportive tax policies to foster domestic innovation and job creation in biotechnology.